Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections
American Journal of Health-System Pharmacy · 07.04.2026 · 83 (8) · 389-397
DOI: 10.1093/ajhp/zxaf301 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 31.10.2025. Verfasst von Jake Crocker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Prisma Health Upstate, Greenville, SC, USA. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Purpose
Emerging data suggest dalbavancin may be used in complicated infections, including bacteremia, prosthetic joint infections, osteomyelitis, and endovascular infections. This study aimed to evaluate the real-world safety and effectiveness of dalbavancin for the treatment of invasive gram-positive infections (GPIs).
Methods
This multicenter, retrospective cohort study included adult patients who received dalbavancin for treatment of confirmed or presumed invasive GPIs. Patients were excluded if they received dalbavancin for chronic suppression. The intention-to-treat (ITT) population comprised patients who received at least 1 dalbavancin dose. The per-protocol (PP) population received at least 2 doses. The primary outcome was clinical failure in the PP group at 90 days post treatment. Secondary outcomes were the proportion of logistical failures, clinical failures, and treatment-emergent adverse events in the ITT group at 90 days post treatment.
Results
Among the 194 patients included in the PP population, 29.4% (57/194) experienced clinical failure at 90 days post treatment. Active intravenous drug use and lack of reliable transportation were factors significantly associated with higher odds of clinical failure in a multivariable regression model.
Conclusion
Dalbavancin is a safe and effective treatment option for invasive GPIs; however, risk factors are associated with higher odds of clinical failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prisma Health Upstate, Greenville, SC, USA.
- University of South Carolina College of Pharmacy, Columbia, SC, USA.
- Prisma Health Richland, Columbia, SC, USA.
- Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
- St. Joseph's/Candler Health System, Savannah, GA, USA.
- University of Oklahoma Medical Center at OU Health, Oklahoma City, OK, USA.
ORCID-Profile: Joseph Sassine
Zitieren
APA
Crocker, J., Yunusa, I., Bookstaver, P. B., Derrick, C., Justo, J. A., Jones, B. M., White, B. P., Sassine, J., Belk, M., & Pizzuti, M. (2026). Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections. American Journal of Health-System Pharmacy, 83(8), 389-397. https://doi.org/10.1093/ajhp/zxaf301
Vancouver
Crocker J, Yunusa I, Bookstaver PB, Derrick C, Justo JA, Jones BM, et al. Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections. American Journal of Health-System Pharmacy. 2026;83(8):389-397. doi:10.1093/ajhp/zxaf301
BibTeX
@article{Crocker2026,
author = {Crocker, Jake and Yunusa, Ismael and Bookstaver, P Brandon and Derrick, Caroline and Justo, Julie Ann and Jones, Bruce M and White, Bryan P and Sassine, Joseph and Belk, Madeline and Pizzuti, Morgan},
title = {Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections},
journal = {American Journal of Health-System Pharmacy},
year = {2026},
volume = {83},
number = {8},
pages = {389--397},
doi = {10.1093/ajhp/zxaf301}
}
EUVIMED